Abstracts Archive - Page 670 of 2607 - ACR Meeting Abstracts

Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 2189 • ACR Convergence 2022
Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study
Janet Poole¹, Deirdre Connolly², Jessica Salazar³ and Kristine Carandang⁴, ¹University of New Mexico, Albuquerque, NM, ²School of Medicine, Trinity College, Dublin, Ireland, ³University of New Mexico, Occupational Therapy Graduate Program, Albuquerque, NM, ⁴Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…
Abstract Number: 2185 • ACR Convergence 2022
Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis
Anne-Renee van der Vuurst de Vries¹, Kathryn Hooper¹, Jonathan Graf², Katie Tuckwell¹ and Joshua Beilke¹, ¹Sonoma Biotherapeutics, South San Francisco, CA, ²Ucsf, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
Abstract Number: 2167 • ACR Convergence 2022
Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
Alyssa Bosso¹, Shervin Assassi², Tracy Frech³, Jessica Gordon⁴, Elana Bernstein⁵, Carrie Richardson⁶, Nora Sandorfi⁷, Laura Hummers⁸, Ami Shah⁹, Dinesh Khanna¹⁰, Lorinda Chung¹¹, Flavia Castelino¹², Faye Hant¹³, Victoria Shanmugam¹⁴, John VanBuren¹⁵, Angela Larkin¹⁶, Luke Evnin¹⁷ and Virginia Steen¹⁸, ¹Medstar Georgetown University Hospital, Washington, DC, ²McGovern Medical School, University of Texas, Houston, TX, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Hospital for Special Surgery, New York, NY, ⁵Columbia University, New York, NY, ⁶Northwestern University, Riverside, IL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Stanford University, Stanford, CA, ¹²Massachusetts General Hospital, Boston, MA, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴George Washington University, Great Falls, VA, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶University of Utah Health, Salt Lake City, UT, ¹⁷Scleroderma Research Foundation, Brisbane, CA, ¹⁸Georgetown University School of Medicine, Washington, DC
Background/Purpose: We sought to describe the autoantibody profile of SSc patients with early disease and examine the clinical, laboratory and prognostic features associated with these…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
Abstract Number: 2196 • ACR Convergence 2022
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Philip J Mease¹, Qi Wei², Michael Chiorean¹, Lulu Iles-Shih¹, Wanessa Matos², Andrew Baumgartner², Sevda Molani², Yeon Mi Hwang², Basazin Belhu² and Jennifer Hadlock², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Institute for Systems Biology, Seattle, WA
Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
Abstract Number: 2195 • ACR Convergence 2022
Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases
Filippo Fagni¹, Katja Schmidt², Daniela Bohr³, Larissa Valor Mendez⁴, Ioanna Minopoulou², Melek Yalcin Mutlu², Fabian Hartmann², Koray Tascilar⁴, Karin Manger⁵, Bernhard Manger², Arnd Kleyer⁴, David Simon⁴, Georg Schett⁶ and Thomas Harrer², ¹University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ²University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Rheumatology Practice Bamberg, Bamberg, Germany, ⁶Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Humoral responses to SARS-CoV-2 vaccination are reduced in patients with immune-mediated inflammatory diseases (IMID), especially when treated with B-cell depletion therapies, leading to increased…
Abstract Number: 2198 • ACR Convergence 2022
How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Alison McClean¹, Nick Bansback¹, Lucy Cheng¹, Fiona Clemont², Mina Tadrous³, Mark Harrison¹ and Mike Law¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Uptake of biosimilars has been suboptimal in North America. In 2019, British Columbia (BC) became the first jurisdiction in North America to require patients…
Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Jeffrey Curtis¹, Yujie Su², Cassie Clinton², Patrick Stewart³, Bryant England⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Bendcare, Boca Raton, FL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵FASTER, Hoover, AL
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
Abstract Number: 2197 • ACR Convergence 2022
Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
Prajakta Masurkar¹, Jennifer Reckleff², Nicole Princic³, Brendan Limone⁴, Hana Schwartz⁴, Elaine Karis⁵, Eric Zollars⁶, Bradley Stolshek⁵ and Karen Costenbader⁷, ¹Amgen, Wylie, TX, ²Amgen, Westlake Village, CA, ³IBM Watson Health, Reading, MA, ⁴IBM Watson Health, Bethesda, MD, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Amgen, Newbury Park, CA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Poor treatment adherence and persistence is an ongoing problem among SLE patients due to complex regimens and may lead to frequent use of high-dose…
Abstract Number: 2193 • ACR Convergence 2022
Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Simon Galmiche¹, Benjamin Thoreau², Stéphane Bretagne³, Alexandre Alanio³, André Paugam⁴, Valérie Bru⁵, Sophie Cassaing⁶, Jean-Pierre Gangneux⁷, Hélène Guégan⁷, Loïc Favennec⁸, Alida Minoza⁹, Florent Morio¹⁰, Julie Bonhomme¹¹, Guillaume Desoubeaux¹², Odile Eloy¹³, Lilia Hasseine¹⁴, Milène Sasso¹⁵, Laurence Millon¹⁶, Anne-Pauline Bellanger¹⁶, Philippe Poirier¹⁷, Maxime Moniot¹⁷, Taieb Chouaki¹⁸, Antoine Huguenin¹⁹, Frédéric Dalle²⁰, Bernard Bouteille²¹, Muriel Nicolas²², Nicole Desbois-Nogard²³, Marie-Elisabeth Bougnoux²⁴, François Danion²⁵, Vincent Poindron²⁶, Antoine Néel²⁷, Karine Boukris-Sitbon²⁸, Fanny Lanternier²⁹ and Benjamin Terrier³⁰, ¹Institut Pasteur, Paris, France, ²AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, ³Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, ⁴Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, ⁵Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, ⁶Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, ⁷Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, ⁸French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, ⁹Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, ¹⁰Parasitologe – Mycologie, CHU de Nantes, Nantes, France, ¹¹Microbiologie, CHU de Caen, Caen, France, ¹²Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, ¹³Microbiologie, Hôpital de Versailles, Le Chesnay, France, ¹⁴Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, ¹⁵Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, ¹⁶Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, ¹⁷Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁸Mycologie – parasitologie, CHU d’Amiens, Amiens, France, ¹⁹Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, ²⁰Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, ²¹Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, ²²Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, ²³Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, ²⁴Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, ²⁵Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁷CHU de Nantes, Nantes, France, ²⁸Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, ²⁹Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, ³⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
Abstract Number: 2201 • ACR Convergence 2022
Increased Economic Burden of Uveitis Among Patients with Psoriasis and Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2022
M. Elaine Husni¹, Jennifer Thorne², Steve Peterson³, Natalie Shiff⁴, Shanti Neff-Baro⁵, Iris Lin⁵, Rachel Teneralli⁵, Oluwakayode Adejoro⁵ and Joseph Merola⁶, ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins Medicine, Baltimore, MD, ³Department of Immunology, Janssen Global Services, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁵Janssen, Horsham, PA, ⁶Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Uveitis occurs more frequently in patients (pts) with psoriatic disease than in the general population,1-2 yet little is known about the increased burden associated…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 2206 • ACR Convergence 2022
Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder¹, Fangya Ma², Josefina Marin³, Minna Kohler⁴, Janeth Yinh⁵, Ari Polachek⁶, Marcos Rosemffet⁷, Ernesto Rodriguez⁸, Ilaria Tinnazzi⁹, Amir Haddad¹⁰, Philippe Carron¹¹, Mariana Alves Ferreira Martins¹², Catherine Bakewell¹³, Fahmeen J. Afgani¹⁴, Richard Cook², Sibel Aydin¹⁵ and Gurjit S. Kaeley¹⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Tel Aviv Medical Center, Tel Aviv, Israel, ⁷Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁸Florida Medical Clinic, Tampa, FL, ⁹Ospedale Sacro Cuore-Don Calabria, Negrar, Italy, ¹⁰Carmel Medical Centre, Haifa, Israel, ¹¹Ghent University Hospital, Ghent, Belgium, ¹²São José Do Rio Preto Medical School, São José do Rio Preto, Brazil, ¹³Intermountain Healthcare, Salt Lake City, UT, ¹⁴Women's College Hospital, Toronto, ON, Canada, ¹⁵University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ¹⁶UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Variability in scoring of sonographic entheseal lesions may be influenced by patient characteristics and sonographer expertise. We aimed to assess inter-rater agreement in scoring…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].